Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis

Open Access
Publisher Website
Google Scholar
Abstract
Background. Clinicopathologic features, treatment, and results are reported for 95 tendosynovial sarcomas identified from a prospective sarcoma data base established at Memorial Sloan‐Kettering Cancer Center (MSKCC) in 1982. Methods. Eighty‐five patients had definitive treatment of the primary tumor at MSKCC. Epithelial sarcomas were excluded. Results. The local recurrence rate was 18%. Survival rates were not influenced by either the method of local treatment or the use of chemotherapy. The overall actuarial survival rate was 59% at 5 years (median, 92 months). For 25 patients who had resection of pulmonary metastases, the 5‐year actuarial survival rate was 43% (median, 22 months) from the time of first thoracotomy. Sex, age, tumor site, and histologic subtype (monophasic versus biphasic) were not significant predictors of survival rates. Regional lymph node metastasis occurred in 3%. The incidence of distant metastasis was 49%, with an associated 5‐year survival rate of 31% (median, 33 months). Tumor size was a highly significant prognostic feature, with 5‐year survival rates of 86yo for patients with tumors smaller than 5 cm and 22% for those with tumors larger than 10 cm (P < 0.00001). Conclusions. Improvement of treatment results for tendosynovial sarcoma will require effective new systemic adjuvant therapeutic strategies. Cancer 1992; 70:484‐489.